Sorin Group (BIT:SRN) announced this week that it landed European CE Mark approval for its latest aortic heart valve, the Crown PRT.
The next-generation device features upgrades to make it more durable, hemodynamic and surgeon-friendly, the company said.
"We are eagerly looking forward to implanting Crown PRT, as this valve incorporates all the latest technological advancements in a modern bioprosthesis, enabling cardiac surgery procedures that are simple, reliable and reproducible," Professor Alain Leguerrier, Chief of the Cardio Thoracic and Vascular Surgery Department, Centre Hospitalier Universitaire de Rennes, France, said on behalf of the company. "Crown PRT meets all the conditions for a remarkable hemodynamic performance and an optimized durability."
The European approval is the latest in a handful of regulatory wins announced by Sorin in recent months. Sorin in April won FDA approval for its Mitroflow bioprosthetic valve with Phospholipid Reduction Treatment as well as expanded CE Mark for its Perceval aortic valve for patients over the age of 65.
